How Is Guselkumab Dosed in PsO, PsA, and IBD?

Join Danielle Gatti Palumbo, PharmD, clinical pharmacist at Northwell Health, Division of Rheumatology in Long Island, New York, as she provides an in-depth review of Guselkumab (Tremfya®) and its use in treating moderate-to-severe plaque psoriasis and active psoriatic arthritis (PsA).

Guselkumab is FDA-approved for psoriasis and PsA and can be used alone or in combination with methotrexate or leflunomide. The standard dosing schedule consists of a 100 mg subcutaneous injection at Week 0 and Week 4, followed by maintenance dosing every 8 weeks.

Before initiating treatment, thorough pre-screening is essential, including TB screening, hepatitis B and C testing, and baseline CBC, BMP, and liver function tests. Regular monitoring ensures patient safety and optimal response to therapy.

Common side effects associated with Guselkumab include upper respiratory infections, injection site reactions, arthralgia, headache, and diarrhea. However, the treatment is well-tolerated and does not require dose adjustments for patients with hepatic or renal impairment.

Guselkumab continues to be a preferred biologic across rheumatology and dermatology, offering targeted IL-23 inhibition for effective management of inflammatory conditions.

For more expert insights and the latest advancements in rheumatology, download the RhAPP ACE App for valuable resources and clinical updates.